On the basis of comprehensive consideration of the needs of prevention and control work in novel coronavirus and the payment ability of local medical insurance funds, local governments should include nucleic acid and antibody testing projects and related consumables carried out in COVID-19 into the catalogue of provincial medical insurance diagnosis and treatment projects according to procedures, and determine the payment terms simultaneously.
Extended data:
In the aspect of nucleic acid detection, if it is really necessary to set up temporary projects to meet the needs of COVID-19 detection fees of public medical institutions, all localities are encouraged to set up projects by means of "separation of technology and consumption".
Consumables such as sample collection, processing, labeling, recovery, diagnosis results and nasopharyngeal swabs used for nucleic acid and antibody detection should be combined into medical service price items; In vitro diagnostic kits are charged at "zero difference rate" outside the medical service price items.
People's Daily Online-National Medical Insurance Bureau: All localities should incorporate nucleic acid testing and other items into medical insurance according to procedures.